Wellgistics Health (NASDAQ:MEDS) Stock Rating Lowered by Wall Street Zen

Wellgistics Health (NASDAQ:MEDS) was downgraded by investment analysts at Wall Street Zen to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Wellgistics Health in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Wellgistics Health Price Performance

Wellgistics Health stock opened at $2.96 on Friday. Wellgistics Health has a fifty-two week low of $0.82 and a fifty-two week high of $73.00. The firm has a fifty day moving average price of $2.79 and a two-hundred day moving average price of $3.87. The firm has a market cap of $9.47 million, a price-to-earnings ratio of -0.06 and a beta of -3.51.

Wellgistics Health (NASDAQ:MEDS) last released its quarterly earnings results on Monday, August 17th. The company reported ($7.13) earnings per share (EPS) for the quarter. The business had revenue of $1.78 million for the quarter.

About Wellgistics Health

Wellgistics Health, Inc is a healthcare technology and pharmaceutical distribution company focused on improving access to prescription medications. The company connects pharmaceutical manufacturers, wholesalers, pharmacies, healthcare providers and patients through technology-enabled services designed to support the movement and dispensing of medications.

Its business includes pharmaceutical distribution and related supply-chain solutions, with an emphasis on helping pharmacies and healthcare organizations source and manage prescription products.